BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
BioCorRx Announces Appointment of Louis Lucido as Board Chair
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
BioCorRx Reports Business Update for the First Quarter of 2025
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
BioCorRx Reports Business Update for the Second Quarter of 2024
From Injections To Edibles, The fight Against Opioid Addiction Is A Multi-Pronged Approach
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
